Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents mixed signals. Financial performance shows modest growth, with strong gains in China but challenges in other regions. Product development updates are positive, with new launches and regulatory progress. However, market strategy and expenses show caution due to potential policy risks and flat margins. Shareholder returns are stable with dividends and repurchases. The Q&A section highlights optimism but also uncertainty in guidance and market conditions. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement.
Key Financial Performance
Total Revenues $3.5 billion, up 3% year-over-year. Growth driven by accelerated growth in cardiovascular portfolio in Greater China and strong generics performance in North America.
Adjusted EBITDA $1 billion. No year-over-year change or reasons for change mentioned.
Adjusted EPS $0.59 per share. No year-over-year change or reasons for change mentioned.
Net Sales in Developed Markets Increased by 1% year-over-year. Growth driven by increased demand for estradiol, strong performance from Breyna, and new product revenue contributions from complex generic launches.
Net Sales in Europe Declined approximately 1% year-over-year. Decline due to softer market conditions in select countries, competitive pressure on Dymista, and certain supply constraints.
Net Sales in Emerging Markets Flat year-over-year. Performance supported by strength in established brands but offset by supply constraints in lower margin ARV portfolio.
Net Sales in JANZ (Japan, Australia, New Zealand) Decreased approximately 2% year-over-year. Decline driven by increased competition in Australia and government price regulations in Japan, partially offset by strong performance from key brands like Creon and Amitiza.
Net Sales in Greater China Increased by 18% year-over-year. Growth driven by favorable market fundamentals (aging population, increasing demand for cardiovascular products), strategic selling and marketing investments, and growth in e-commerce platforms.
Adjusted Gross Margin 56%, flat year-over-year. Margins benefited from favorable product mix.
Free Cash Flow $348 million, inclusive of transaction and restructuring-related costs and taxes. Excluding these items, free cash flow would have been $459 million. No year-over-year change or reasons for change mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EFFEXOR: Launched in Japan for generalized anxiety disorder, with expectations for growth and additional launches in the coming years.
XULANE LO: A weekly contraceptive patch with regulatory decision expected in the second half of the year.
Fast-acting meloxicam: NDA accepted for review by FDA for moderate-to-severe acute pain, with regulatory decision expected by year-end.
Creon: Phase III study in Europe showed benefits of dose escalation for pancreatic exocrine insufficiency treatment, with plans for label update in 2027.
Generic to Abilify Maintena: Approval secured and on track for U.S. launch by year-end.
Greater China: Achieved 18% year-over-year growth driven by cardiovascular portfolio and e-commerce sales.
Japan: Momentum building with EFFEXOR launch and anticipated regulatory decisions for pitolisant and Nefecon.
Cost structure optimization: Progress made through enterprise-wide strategic review to improve resource allocation and drive operational efficiency.
Free cash flow: Generated $348 million in Q1, with $459 million excluding transaction and restructuring costs.
Capital allocation: Disciplined approach with focus on dividends, share repurchases, and business investments for sustainable growth.
Business development: Targeting in-market, accretive opportunities aligned with capabilities to strengthen growth profile.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Constraints: Supply constraints in the lower-margin ARV portfolio and certain products in Europe impacted sales and performance.
Competitive Pressures: Anticipated competitive pressure on products like Dymista in Europe and increased competition in Australia affected sales.
Regulatory Challenges: Government price regulations in Japan negatively impacted sales in the JANZ segment.
Market Conditions: Softer market conditions in select European countries led to a decline in net sales.
Operational Risks: Temporary supply constraints related to lower-margin generics and additional competitive pressure across generics in developed markets pose risks to revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects stronger growth in Greater China in the range of mid- to high-single digits, driven by favorable market fundamentals and strategic investments. Total revenues, adjusted EBITDA, and adjusted EPS are expected to be weighted to the second half of 2026, reflecting product seasonality and new product launches.
Product Launches and Approvals: The company anticipates regulatory decisions for five product candidates in the second half of 2026, including XULANE LO and fast-acting meloxicam. Additionally, the generic to Abilify Maintena is on track to launch in the U.S. by year-end. The company also expects regulatory decisions for pitolisant in Japan and plans to file a type 2 variation for Creon in Europe by the end of 2026.
Pipeline Development: Phase III programs for selatogrel and cenerimod are progressing, with full enrollment for selatogrel expected by the end of 2026 and results for cenerimod studies anticipated in the first half of 2027. The company is also advancing its generic pipeline, with FDA decisions expected for iron ferric carboxymaltose injection and rotigotine patch in 2026.
Capital Allocation: The company plans to deploy over $2.5 billion in cash during 2026, balancing shareholder returns through dividends and share repurchases with investments in business growth. Free cash flow is expected to increase in the second half of the year.
Market Trends and Regional Performance: Growth in Greater China is expected to accelerate due to an aging population and increased demand for cardiovascular products. Temporary supply constraints and competitive pressures are anticipated in developed markets, but these are expected to be offset by delayed competition for Amitiza in Japan and favorable foreign currency exchange rates.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Payments: During the quarter, $140 million of capital was returned to shareholders through dividends.
Share Repurchase Program: The company intends to return capital to shareholders through share repurchases as part of its balanced capital allocation strategy.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What contributed to the strong incremental growth in China and how does the company view its durability?
A:The growth in China was driven by strong execution, commercial efforts, and investments in e-commerce. The company has increased its growth expectations for China from low-single digits to mid- to high-single digits. However, they remain cautious due to potential policy risks and will monitor the situation through Q2.
Q:What are the biggest opportunities in the pipeline over the next 12 months?
A:The biggest opportunities include the estrogen patch decision by July, fast-acting meloxicam in Q4, cenerimod readouts in the first half of 2027, and selatogrel in late 2027. The company is confident in the clinical data and expects approvals as planned.
Q:What are the drivers of free cash flow year-over-year and details on the selatogrel trial design?
A:Free cash flow was impacted by timing, net working capital, business growth, and increased one-time costs. The selatogrel trial uses a ranking endpoint designed with the FDA, focusing on the severity of MI events. The study is powered to show a 20% relative risk reduction.
Q:What is the status of fast-acting meloxicam and its expected label?
A:The company expects the FDA to provide the PDUFA date soon and anticipates opioid-sparing language to be included in the label. The product is positioned as a non-opioid option for moderate-to-severe acute pain, with a sales force of 150-200 reps planned for its launch.
Q:What is the company's approach to business development and the CFO transition?
A:The company focuses on in-market accretive assets and balanced capital allocation. The CFO transition will not change financial policies, and the interim CFO has strong experience and understanding of the business.
Q:What is the company's strategy for the GLP-1 market and the ARV business?
A:The company aims to be a significant player in the GLP-1 market, focusing on the U.S. and leveraging its device expertise. For the ARV business, supply constraints are being mitigated, and risks are included in the updated forecast.
Q:How does the company plan to achieve its long-term growth target of 4% organic growth?
A:The company expects to achieve 4% organic growth by 2030, supported by clinical readouts, product launches, and disciplined execution. The strong start with 3% growth in Q1 indicates progress toward this goal.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the expected label for fast-acting meloxicam, particularly regarding the placement of opioid-sparing language. Additionally, they did not provide a clear timeline for achieving the 4% organic growth target beyond stating it would be by 2030.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACOG American
AMI Phase
Authority type
CEO Interim
CEO start
CFO Campbell
CFO year
Campbell Chief
Campbell step
China contributor
EFFEXOR adult
EFFEXOR launch
Europe end
Europe manufacturing
Europe standard
FDA PDUFA
FDA decision
FDA dose
German Health
III program
III study
Japan track
PDUFA goal
Phase III
condition
congress
enrollment
generic track
goal date
milestone
program selatogrel
role
selatogrel cenerimod
track PDUFA
update
VTRS Transcript
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary presents mixed signals. Financial performance shows modest growth, with strong gains in China but challenges in other regions. Product development updates are positive, with new launches and regulatory progress. However, market strategy and expenses show caution due to potential policy risks and flat margins. Shareholder returns are stable with dividends and repurchases. The Q&A section highlights optimism but also uncertainty in guidance and market conditions. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement.
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong financial guidance for 2025, cost-saving initiatives, and a focus on pipeline development with promising product launches. Shareholder returns are robust, and the company is exploring strategic M&A opportunities. The Q&A section highlighted positive sentiment, with management addressing concerns effectively. Despite some uncertainties, such as the exact revenue impact of new products, the overall sentiment is positive, with raised guidance, stable margins, and strong shareholder returns outweighing potential risks.
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral12-3
VTRS Slides
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan2026-02-26
Viatris Q3 2025 presentation slides: Raises full-year guidance despite GAAP losses2025-11-06
Viatris Q2 2025 slides: reaffirms guidance despite Indore challenges2025-08-07
Viatris Q1 2025 slides: maintains guidance despite revenue decline, pipeline advances2025-05-08
VTRS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
